Jean‐Jacques Kiladjian

28.8k total citations · 5 hit papers
381 papers, 12.0k citations indexed

About

Jean‐Jacques Kiladjian is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Jean‐Jacques Kiladjian has authored 381 papers receiving a total of 12.0k indexed citations (citations by other indexed papers that have themselves been cited), including 356 papers in Genetics, 259 papers in Hematology and 108 papers in Rheumatology. Recurrent topics in Jean‐Jacques Kiladjian's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (348 papers), Chronic Myeloid Leukemia Treatments (164 papers) and Acute Myeloid Leukemia Research (112 papers). Jean‐Jacques Kiladjian is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (348 papers), Chronic Myeloid Leukemia Treatments (164 papers) and Acute Myeloid Leukemia Research (112 papers). Jean‐Jacques Kiladjian collaborates with scholars based in France, United States and Italy. Jean‐Jacques Kiladjian's co-authors include Claire Harrison, Alessandro M. Vannucchi, Francisco Cervantes, Ruben A. Mesa, Tiziano Barbui, Heinz Gisslinger, Francesco Passamonti, Srđan Verstovšek, Giovanni Barosi and Bruno Cassinat and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Jean‐Jacques Kiladjian

363 papers receiving 11.8k citations

Hit Papers

JAK Inhibition with Ruxolitinib versus Best Availa... 2002 2026 2010 2018 2012 2002 2015 2016 2021 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
    2012 1.2k citations Claire Harrison, Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →
  2. Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
    2002 843 citations Nicole Casadevall, Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →
  3. Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
    2015 594 citations Alessandro M. Vannucchi, Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →
  4. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    2016 350 citations Claire Harrison, Alessandro M. Vannucchi et al. Leukemia profile →
  5. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
    2021 249 citations Jean‐Jacques Kiladjian et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean‐Jacques Kiladjian France 49 9.4k 7.4k 5.4k 4.0k 1.2k 381 12.0k
Francesco Passamonti Italy 59 14.9k 1.6× 11.3k 1.5× 8.6k 1.6× 5.8k 1.5× 580 0.5× 316 17.3k
Claire Harrison United Kingdom 58 12.8k 1.4× 9.4k 1.3× 7.7k 1.4× 5.1k 1.3× 579 0.5× 452 15.0k
Francisco Cervantes Spain 64 15.8k 1.7× 14.5k 2.0× 7.6k 1.4× 7.1k 1.8× 691 0.6× 321 20.0k
Alessandro M. Vannucchi Italy 78 19.2k 2.1× 14.8k 2.0× 12.1k 2.2× 7.7k 2.0× 992 0.8× 549 23.0k
Fabrizio Pane Italy 42 4.9k 0.5× 6.7k 0.9× 1.9k 0.3× 2.7k 0.7× 648 0.5× 289 9.4k
John Mascarenhas United States 40 3.7k 0.4× 3.2k 0.4× 2.7k 0.5× 1.5k 0.4× 1.2k 0.9× 358 6.4k
Enrica Morra Italy 46 5.4k 0.6× 4.5k 0.6× 2.4k 0.4× 1.2k 0.3× 1.3k 1.1× 238 8.7k
Bruno Varet France 37 2.6k 0.3× 4.1k 0.6× 1.7k 0.3× 1.0k 0.3× 1.4k 1.2× 145 7.6k
Thierry Façon France 69 3.4k 0.4× 17.1k 2.3× 13.1k 2.4× 1.0k 0.3× 1.5k 1.2× 458 21.9k
Sigurður Y. Kristinsson Sweden 46 2.6k 0.3× 3.9k 0.5× 2.2k 0.4× 597 0.2× 594 0.5× 142 6.0k

Countries citing papers authored by Jean‐Jacques Kiladjian

Since Specialization
Citations

This map shows the geographic impact of Jean‐Jacques Kiladjian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean‐Jacques Kiladjian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean‐Jacques Kiladjian more than expected).

Fields of papers citing papers by Jean‐Jacques Kiladjian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean‐Jacques Kiladjian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean‐Jacques Kiladjian. The network helps show where Jean‐Jacques Kiladjian may publish in the future.

Co-authorship network of co-authors of Jean‐Jacques Kiladjian

This figure shows the co-authorship network connecting the top 25 collaborators of Jean‐Jacques Kiladjian. A scholar is included among the top collaborators of Jean‐Jacques Kiladjian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean‐Jacques Kiladjian. Jean‐Jacques Kiladjian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ganesan, Saravanan, Fabien Guidez, Nabih Maslah, et al.. (2024). Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis. JCI Insight. 9(23). 1 indexed citations
2.
Oh, Stephen T., Ruben A. Mesa, Claire Harrison, et al.. (2023). Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Advances. 7(19). 5835–5842. 39 indexed citations
3.
Kiladjian, Jean‐Jacques & Bruno Cassinat. (2023). Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. American Journal of Hematology. 98(5). 794–800. 11 indexed citations
4.
Verstovšek, Srđan, Ivan Krečak, Florian H. Heidel, et al.. (2023). Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project. Biomedicines. 11(7). 1925–1925. 16 indexed citations
5.
Lambert, Juliette, Joseph Saliba, Carolina Calderón, et al.. (2021). PPARγ agonists promote the resolution of myelofibrosis in preclinical models. Journal of Clinical Investigation. 131(11). 6 indexed citations
6.
Maslah, Nabih, Emmanuelle Verger, Christine Chomienne, et al.. (2021). Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement. British Journal of Haematology. 196(3). 676–680. 7 indexed citations
7.
8.
Harrison, Claire, Nicolaas Schaap, Alessandro M. Vannucchi, et al.. (2020). Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American Journal of Hematology. 95(6). 594–603. 104 indexed citations
9.
Soret, Juliette, Nicolas Gauthier, Emmanuelle Verger, et al.. (2020). SF3B1 mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). Blood. 136(Supplement 1). 1–1. 2 indexed citations
10.
Cassinat, Bruno, Barbara Mora, Emmanuelle Verger, et al.. (2020). Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Advances. 4(15). 3708–3715. 30 indexed citations
11.
Pangallo, Joseph, Jean‐Jacques Kiladjian, Bruno Cassinat, et al.. (2020). Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations. Blood. 135(13). 1032–1043. 11 indexed citations
12.
Fenaux, Pierre, Jean‐Jacques Kiladjian, & Uwe Platzbecker. (2019). Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. Blood. 133(8). 790–794. 69 indexed citations
13.
14.
Mesa, Ruben A., Jean‐Jacques Kiladjian, John Catalano, et al.. (2017). SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis. Journal of Clinical Oncology. 35(34). 3844–3850. 238 indexed citations
15.
Birgegård, Gunnar, Yasin Folkvaljon, Hans Garmo, et al.. (2016). Rate Of Malignant Transformation In High Risk Et During 5 Years Of Follow-Up Of Cytoreductive Therapy. Haematologica. 101. 96–96. 1 indexed citations
16.
Tefferi, Ayalew, Francesco Passamonti, Tiziano Barbui, et al.. (2013). Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. Blood. 122(21). 394–394. 24 indexed citations
17.
Harrison, Claire, Jean‐Jacques Kiladjian, & Giovanni Barosi. (2012). Dr. Harrison and colleagues reply. New England Journal of Medicine. 366(21). 2032–2034. 1 indexed citations
18.
Smalberg, Jasper H., Lidia R. Arends, Dominique Valla, et al.. (2012). Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 120(25). 4921–4928. 243 indexed citations
19.
Kiladjian, Jean‐Jacques, Francisco Cervantes, Frank W.G. Leebeek, et al.. (2008). The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 111(10). 4922–4929. 227 indexed citations
20.
Kiladjian, Jean‐Jacques, Nahed El-Kassar, Gilles Hetet, et al.. (1997). Study of the thrombopoietin receptor in essential thrombocythemia. Leukemia. 11(11). 1821–1826. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Passamonti Breakdown of academic impact, for papers by Claire Harrison Breakdown of academic impact, for papers by Francisco Cervantes Breakdown of academic impact, for papers by Alessandro M. Vannucchi Breakdown of academic impact, for papers by Fabrizio Pane Breakdown of academic impact, for papers by John Mascarenhas Breakdown of academic impact, for papers by Enrica Morra Breakdown of academic impact, for papers by Bruno Varet Breakdown of academic impact, for papers by Thierry Façon Breakdown of academic impact, for papers by Sigurður Y. Kristinsson
Rankless by CCL
2026